Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lenalidomide and nivolumab work in treating patients
with multiple myeloma that has come back or does not respond to treatment. Drugs used in
chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer
cells to grow and spread. Giving lenalidomide and nivolumab may work better in treating
patients with multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Yvonne Efebera
Collaborators:
American Cancer Society, Inc. Bristol-Myers Squibb National Cancer Institute (NCI)